<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32503641</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>01</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1750-1326</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Jun</Month><Day>05</Day></PubDate></JournalIssue><Title>Molecular neurodegeneration</Title><ISOAbbreviation>Mol Neurodegener</ISOAbbreviation></Journal><ArticleTitle>Harnessing regulatory T cell neuroprotective activities for treatment of neurodegenerative disorders.</ArticleTitle><Pagination><StartPage>32</StartPage><MedlinePgn>32</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">32</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13024-020-00375-7</ELocationID><Abstract><AbstractText>Emerging evidence demonstrates that adaptive immunity influences the pathobiology of neurodegenerative disorders. Misfolded aggregated self-proteins can break immune tolerance leading to the induction of autoreactive effector T cells (Teffs) with associated decreases in anti-inflammatory neuroprotective regulatory T cells (Tregs). An imbalance between Teffs and Tregs leads to microglial activation, inflammation and neuronal injury. The cascade of such a disordered immunity includes the drainage of the aggregated protein antigens into cervical lymph nodes serving to amplify effector immune responses. Both preclinical and clinical studies demonstrate transformation of this altered immunity for therapeutic gain. We posit that the signs and symptoms of common neurodegenerative disorders such as Alzheimer's and Parkinson's diseases, amyotrophic lateral sclerosis, and stroke can be attenuated by boosting Treg activities.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Machhi</LastName><ForeName>Jatin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Neuroscience, Center for Neurodegenerative Disorders, University of Nebraska Medical Center, Omaha, NE, 68198-5880, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kevadiya</LastName><ForeName>Bhavesh D</ForeName><Initials>BD</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Neuroscience, Center for Neurodegenerative Disorders, University of Nebraska Medical Center, Omaha, NE, 68198-5880, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, School of Medicine, Stanford University, Palo Alto, 94304, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muhammad</LastName><ForeName>Ijaz Khan</ForeName><Initials>IK</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Neuroscience, Center for Neurodegenerative Disorders, University of Nebraska Medical Center, Omaha, NE, 68198-5880, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacy, University of Swabi, Anbar Swabi, 23561, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herskovitz</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Neuroscience, Center for Neurodegenerative Disorders, University of Nebraska Medical Center, Omaha, NE, 68198-5880, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, 68198-5880, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olson</LastName><ForeName>Katherine E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Neuroscience, Center for Neurodegenerative Disorders, University of Nebraska Medical Center, Omaha, NE, 68198-5880, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mosley</LastName><ForeName>R Lee</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Neuroscience, Center for Neurodegenerative Disorders, University of Nebraska Medical Center, Omaha, NE, 68198-5880, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gendelman</LastName><ForeName>Howard E</ForeName><Initials>HE</Initials><Identifier Source="ORCID">0000-0002-7831-0370</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Neuroscience, Center for Neurodegenerative Disorders, University of Nebraska Medical Center, Omaha, NE, 68198-5880, USA. hegendel@unmc.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, 68198-5880, USA. hegendel@unmc.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 MH062261</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG043540</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS034239</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH115860</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 DA028555</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Neurodegener</MedlineTA><NlmUniqueID>101266600</NlmUniqueID><ISSNLinking>1750-1326</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000066829" MajorTopicYN="Y">Neuroprotection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050378" MajorTopicYN="N">T-Lymphocytes, Regulatory</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Dendritic cells</Keyword><Keyword MajorTopicYN="N">Effector T cells (Teffs)</Keyword><Keyword MajorTopicYN="N">Immune transformation</Keyword><Keyword MajorTopicYN="N">Microglia</Keyword><Keyword MajorTopicYN="N">Neurodegenerative disorders</Keyword><Keyword MajorTopicYN="N">Regulatory T cells (Tregs)</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>4</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32503641</ArticleId><ArticleId IdType="pmc">PMC7275301</ArticleId><ArticleId IdType="doi">10.1186/s13024-020-00375-7</ArticleId><ArticleId IdType="pii">10.1186/s13024-020-00375-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Reynolds AD, Stone DK, Hutter JA, Benner EJ, Mosley RL, Gendelman HE. Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease. J Immunol. 2010;184:2261&#x2013;2271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2824790</ArticleId><ArticleId IdType="pubmed">20118279</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson KM, Olson KE, Estes KA, Flanagan K, Gendelman HE, Mosley RL. Dual destructive and protective roles of adaptive immunity in neurodegenerative disorders. Transl Neurodegener. 2014;3:25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4323229</ArticleId><ArticleId IdType="pubmed">25671101</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendelman HE, Mosley RL. A Perspective on Roles Played by Innate and Adaptive Immunity in the Pathobiology of Neurodegenerative Disorders. J Neuroimmune Pharmacol. 2015;10:645&#x2013;650.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4662620</ArticleId><ArticleId IdType="pubmed">26520433</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelhardt B, Vajkoczy P, Weller RO. The movers and shapers in immune privilege of the CNS. Nat Immunol. 2017;18:123&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">28092374</ArticleId></ArticleIdList></Reference><Reference><Citation>Prinz M, Priller J. The role of peripheral immune cells in the CNS in steady state and disease. Nat Neurosci. 2017;20:136&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">28092660</ArticleId></ArticleIdList></Reference><Reference><Citation>Radjavi A, Smirnov I, Kipnis J. Brain antigen-reactive CD4+ T cells are sufficient to support learning behavior in mice with limited T cell repertoire. Brain Behav Immun. 2014;35:58&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3858511</ArticleId><ArticleId IdType="pubmed">24012647</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziv Y, Avidan H, Pluchino S, Martino G, Schwartz M. Synergy between immune cells and adult neural stem/progenitor cells promotes functional recovery from spinal cord injury. Proc Natl Acad Sci U S A. 2006;103:13174&#x2013;13179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1559772</ArticleId><ArticleId IdType="pubmed">16938843</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans FL, Dittmer M, de la Fuente AG, Fitzgerald DC. Protective and Regenerative Roles of T Cells in Central Nervous System Disorders. Front Immunol. 2019;10:2171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6751344</ArticleId><ArticleId IdType="pubmed">31572381</ArticleId></ArticleIdList></Reference><Reference><Citation>Amor S, Woodroofe MN. Innate and adaptive immune responses in neurodegeneration and repair. Immunology. 2014;141:287&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3930367</ArticleId><ArticleId IdType="pubmed">23758741</ArticleId></ArticleIdList></Reference><Reference><Citation>Stower H. Searching for Alzheimer&#x2019;s disease therapies. Nature Medicine. 2018;24:894&#x2013;897.</Citation><ArticleIdList><ArticleId IdType="pubmed">29988132</ArticleId></ArticleIdList></Reference><Reference><Citation>Deczkowska A, Schwartz M. Targeting neuro-immune communication in neurodegeneration: Challenges and opportunities. J Exp Med. 2018;215:2702&#x2013;2704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6219738</ArticleId><ArticleId IdType="pubmed">30301785</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, Leak RK, Thomson AW, Yu F, Xia Y, Wechsler LR, Chen J. Promises and limitations of immune cell-based therapies in neurological disorders. Nat Rev Neurol. 2018;14:559&#x2013;568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6237550</ArticleId><ArticleId IdType="pubmed">29925925</ArticleId></ArticleIdList></Reference><Reference><Citation>Brochard V, Combadiere B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V, Bonduelle O, Alvarez-Fischer D, Callebert J, Launay JM, et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest. 2009;119:182&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2613467</ArticleId><ArticleId IdType="pubmed">19104149</ArticleId></ArticleIdList></Reference><Reference><Citation>Louveau A, Harris TH, Kipnis J. Revisiting the Mechanisms of CNS Immune Privilege. Trends Immunol. 2015;36:569&#x2013;577.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4593064</ArticleId><ArticleId IdType="pubmed">26431936</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey SL, Carpentier PA, McMahon EJ, Begolka WS, Miller SD. Innate and adaptive immune responses of the central nervous system. Crit Rev Immunol. 2006;26:149&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">16700651</ArticleId></ArticleIdList></Reference><Reference><Citation>Benner EJ, Banerjee R, Reynolds AD, Sherman S, Pisarev VM, Tsiperson V, Nemachek C, Ciborowski P, Przedborski S, Mosley RL, Gendelman HE. Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS One. 2008;3:e1376.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2147051</ArticleId><ArticleId IdType="pubmed">18167537</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiyota T, Machhi J, Lu Y, Dyavarshetty B, Nemati M, Yokoyama I, Mosley RL, Gendelman HE. Granulocyte-macrophage colony-stimulating factor neuroprotective activities in Alzheimer's disease mice. J Neuroimmunol. 2018;319:80&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5916331</ArticleId><ArticleId IdType="pubmed">29573847</ArticleId></ArticleIdList></Reference><Reference><Citation>Dombrowski Y, O'Hagan T, Dittmer M, Penalva R, Mayoral SR, Bankhead P, Fleville S, Eleftheriadis G, Zhao C, Naughton M, et al. Regulatory T cells promote myelin regeneration in the central nervous system. Nat Neurosci. 2017;20:674&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5409501</ArticleId><ArticleId IdType="pubmed">28288125</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff RM, Brown MA. Innate immunity in the central nervous system. J Clin Invest. 2012;122:1164&#x2013;1171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3314450</ArticleId><ArticleId IdType="pubmed">22466658</ArticleId></ArticleIdList></Reference><Reference><Citation>Appel SH, Smith RG, Engelhardt JI, Stefani E. Evidence for autoimmunity in amyotrophic lateral sclerosis. J Neurol Sci. 1993;118:169&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">8229065</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Beers DR, Liao B, Henkel JS, Appel SH. Regulatory T lymphocytes from ALS mice suppress microglia and effector T lymphocytes through different cytokine-mediated mechanisms. Neurobiol Dis. 2012;48:418&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3897268</ArticleId><ArticleId IdType="pubmed">22820142</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds AD, Banerjee R, Liu J, Gendelman HE, Mosley RL. Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease. J Leukoc Biol. 2007;82:1083&#x2013;1094.</Citation><ArticleIdList><ArticleId IdType="pubmed">17675560</ArticleId></ArticleIdList></Reference><Reference><Citation>Baek H, Ye M, Kang GH, Lee C, Lee G, Choi DB, Jung J, Kim H, Lee S, Kim JS, et al. Neuroprotective effects of CD4+CD25+Foxp3+ regulatory T cells in a 3xTg-AD Alzheimer's disease model. Oncotarget. 2016;7:69347&#x2013;69357.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5342482</ArticleId><ArticleId IdType="pubmed">27713140</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendelman HE, Zhang Y, Santamaria P, Olson KE, Schutt CR, Bhatti D, Shetty BLD, Lu Y, Estes KA, Standaert DG, et al. Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson's disease trial. NPJ Parkinsons Dis. 2017;3:10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5445595</ArticleId><ArticleId IdType="pubmed">28649610</ArticleId></ArticleIdList></Reference><Reference><Citation>Olson KE, Kosloski-Bilek LM, Anderson KM, Diggs BJ, Clark BE, Gledhill JM, Jr, Shandler SJ, Mosley RL, Gendelman HE. Selective VIP Receptor Agonists Facilitate Immune Transformation for Dopaminergic Neuroprotection in MPTP-Intoxicated Mice. J Neurosci. 2015;35:16463&#x2013;16478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4679826</ArticleId><ArticleId IdType="pubmed">26674871</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosloski LM, Kosmacek EA, Olson KE, Mosley RL, Gendelman HE. GM-CSF induces neuroprotective and anti-inflammatory responses in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxicated mice. J Neuroimmunol. 2013;265:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3872482</ArticleId><ArticleId IdType="pubmed">24210793</ArticleId></ArticleIdList></Reference><Reference><Citation>Liesz A, Zhou W, Na SY, Hammerling GJ, Garbi N, Karcher S, Mracsko E, Backs J, Rivest S, Veltkamp R. Boosting regulatory T cells limits neuroinflammation in permanent cortical stroke. J Neurosci. 2013;33:17350&#x2013;17362.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6618366</ArticleId><ArticleId IdType="pubmed">24174668</ArticleId></ArticleIdList></Reference><Reference><Citation>Laurie C, Reynolds A, Coskun O, Bowman E, Gendelman HE, Mosley RL. CD4+ T cells from Copolymer-1 immunized mice protect dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J Neuroimmunol. 2007;183:60&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">17196666</ArticleId></ArticleIdList></Reference><Reference><Citation>Benner EJ, Mosley RL, Destache CJ, Lewis TB, Jackson-Lewis V, Gorantla S, Nemachek C, Green SR, Przedborski S, Gendelman HE. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A. 2004;101:9435&#x2013;9440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC438994</ArticleId><ArticleId IdType="pubmed">15197276</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui G, Zhang Y, Gong Z, Zhang JZ, Zang YQ. Induction of CD4+CD25+Foxp3+ regulatory T cell response by glatiramer acetate in type 1 diabetes. Cell Res. 2009;19:574&#x2013;583.</Citation><ArticleIdList><ArticleId IdType="pubmed">19188932</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivisakk P, Tucky B, Wei T, Campbell JJ, Ransohoff RM. Human cerebrospinal fluid contains CD4+ memory T cells expressing gut- or skin-specific trafficking determinants: relevance for immunotherapy. BMC Immunol. 2006;7:14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1539023</ArticleId><ArticleId IdType="pubmed">16824229</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff RM, Engelhardt B. The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol. 2012;12:623&#x2013;635.</Citation><ArticleIdList><ArticleId IdType="pubmed">22903150</ArticleId></ArticleIdList></Reference><Reference><Citation>Korin B, Ben-Shaanan TL, Schiller M, Dubovik T, Azulay-Debby H, Boshnak NT, Koren T, Rolls A. High-dimensional, single-cell characterization of the brain's immune compartment. Nat Neurosci. 2017;20:1300&#x2013;1309.</Citation><ArticleIdList><ArticleId IdType="pubmed">28758994</ArticleId></ArticleIdList></Reference><Reference><Citation>Goverman J. Autoimmune T cell responses in the central nervous system. Nat Rev Immunol. 2009;9:393&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2813731</ArticleId><ArticleId IdType="pubmed">19444307</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawakami N, Lassmann S, Li Z, Odoardi F, Ritter T, Ziemssen T, Klinkert WE, Ellwart JW, Bradl M, Krivacic K, et al. The activation status of neuroantigen-specific T cells in the target organ determines the clinical outcome of autoimmune encephalomyelitis. J Exp Med. 2004;199:185&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2211765</ArticleId><ArticleId IdType="pubmed">14734524</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartholomaus I, Kawakami N, Odoardi F, Schlager C, Miljkovic D, Ellwart JW, Klinkert WE, Flugel-Koch C, Issekutz TB, Wekerle H, Flugel A. Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions. Nature. 2009;462:94&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">19829296</ArticleId></ArticleIdList></Reference><Reference><Citation>van Zwam M, Huizinga R, Heijmans N, van Meurs M, Wierenga-Wolf AF, Melief MJ. Hintzen RQ, t Hart BA, Amor S, Boven LA, Laman JD: Surgical excision of CNS-draining lymph nodes reduces relapse severity in chronic-relapsing experimental autoimmune encephalomyelitis. J Pathol. 2009;217:543&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pubmed">19023878</ArticleId></ArticleIdList></Reference><Reference><Citation>Filiano AJ, Xu Y, Tustison NJ, Marsh RL, Baker W, Smirnov I, Overall CC, Gadani SP, Turner SD, Weng Z, et al. Unexpected role of interferon-gamma in regulating neuronal connectivity and social behaviour. Nature. 2016;535:425&#x2013;429.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4961620</ArticleId><ArticleId IdType="pubmed">27409813</ArticleId></ArticleIdList></Reference><Reference><Citation>Derecki NC, Cardani AN, Yang CH, Quinnies KM, Crihfield A, Lynch KR, Kipnis J. Regulation of learning and memory by meningeal immunity: a key role for IL-4. J Exp Med. 2010;207:1067&#x2013;1080.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2867291</ArticleId><ArticleId IdType="pubmed">20439540</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao W, Zheng H. Peripheral immune system in aging and Alzheimer's disease. Mol Neurodegener. 2018;13:51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6169078</ArticleId><ArticleId IdType="pubmed">30285785</ArticleId></ArticleIdList></Reference><Reference><Citation>Widner H, Brundin P. Immunological aspects of grafting in the mammalian central nervous system. A review and speculative synthesis. Brain Res. 1988;472:287&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7133672</ArticleId><ArticleId IdType="pubmed">3066438</ArticleId></ArticleIdList></Reference><Reference><Citation>Fine A. Transplantation in the central nervous system. Sci Am. 1986;255:52&#x2013;58B.</Citation><ArticleIdList><ArticleId IdType="pubmed">3749854</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen MK, Mestre H, Nedergaard M. The glymphatic pathway in neurological disorders. Lancet Neurol. 2018;17:1016&#x2013;1024.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6261373</ArticleId><ArticleId IdType="pubmed">30353860</ArticleId></ArticleIdList></Reference><Reference><Citation>Iliff JJ, Lee H, Yu M, Feng T, Logan J, Nedergaard M, Benveniste H. Brain-wide pathway for waste clearance captured by contrast-enhanced MRI. J Clin Invest. 2013;123:1299&#x2013;1309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3582150</ArticleId><ArticleId IdType="pubmed">23434588</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelhardt B, Carare RO, Bechmann I, Flugel A, Laman JD, Weller RO. Vascular, glial, and lymphatic immune gateways of the central nervous system. Acta Neuropathol. 2016;132:317&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4992028</ArticleId><ArticleId IdType="pubmed">27522506</ArticleId></ArticleIdList></Reference><Reference><Citation>Louveau A, Plog BA, Antila S, Alitalo K, Nedergaard M, Kipnis J. Understanding the functions and relationships of the glymphatic system and meningeal lymphatics. J Clin Invest. 2017;127:3210&#x2013;3219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5669566</ArticleId><ArticleId IdType="pubmed">28862640</ArticleId></ArticleIdList></Reference><Reference><Citation>Iliff JJ, Wang M, Liao Y, Plogg BA, Peng W, Gundersen GA, Benveniste H, Vates GE, Deane R, Goldman SA, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta. Sci Transl Med. 2012;4:147ra111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3551275</ArticleId><ArticleId IdType="pubmed">22896675</ArticleId></ArticleIdList></Reference><Reference><Citation>Korin B, Dubovik T, Rolls A. Mass cytometry analysis of immune cells in the brain. Nat Protoc. 2018;13:377&#x2013;391.</Citation><ArticleIdList><ArticleId IdType="pubmed">29370157</ArticleId></ArticleIdList></Reference><Reference><Citation>Raphael I, Nalawade S, Eagar TN, Forsthuber TG. T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. Cytokine. 2015;74:5&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4416069</ArticleId><ArticleId IdType="pubmed">25458968</ArticleId></ArticleIdList></Reference><Reference><Citation>Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol. 2000;164:6166&#x2013;6173.</Citation><ArticleIdList><ArticleId IdType="pubmed">10843666</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff RM, Perry VH. Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol. 2009;27:119&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">19302036</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Y, Le W. Differential Roles of M1 and M2 Microglia in Neurodegenerative Diseases. Mol Neurobiol. 2016;53:1181&#x2013;1194.</Citation><ArticleIdList><ArticleId IdType="pubmed">25598354</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiyota T, Machhi J, Lu Y, Dyavarshetty B, Nemati M, Zhang G, Mosley RL, Gelbard HA, Gendelman HE. URMC-099 facilitates amyloid-beta clearance in a murine model of Alzheimer's disease. J Neuroinflammation. 2018;15:137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5935963</ArticleId><ArticleId IdType="pubmed">29729668</ArticleId></ArticleIdList></Reference><Reference><Citation>Appel SH, Beers DR, Henkel JS. T cell-microglial dialogue in Parkinson's disease and amyotrophic lateral sclerosis: are we listening? Trends Immunol. 2010;31:7&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4126423</ArticleId><ArticleId IdType="pubmed">19879804</ArticleId></ArticleIdList></Reference><Reference><Citation>Colombo E, Farina C. Astrocytes: Key Regulators of Neuroinflammation. Trends Immunol. 2016;37:608&#x2013;620.</Citation><ArticleIdList><ArticleId IdType="pubmed">27443914</ArticleId></ArticleIdList></Reference><Reference><Citation>Li K, Li J, Zheng J, Qin S. Reactive Astrocytes in Neurodegenerative Diseases. Aging Dis. 2019;10:664&#x2013;675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6538217</ArticleId><ArticleId IdType="pubmed">31165009</ArticleId></ArticleIdList></Reference><Reference><Citation>Phatnani H, Maniatis T. Astrocytes in neurodegenerative disease. Cold Spring Harb Perspect Biol. 2015;7:a020628.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4448607</ArticleId><ArticleId IdType="pubmed">25877220</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow SA, Barres BA. Reactive Astrocytes: Production, Function, and Therapeutic Potential. Immunity. 2017;46:957&#x2013;967.</Citation><ArticleIdList><ArticleId IdType="pubmed">28636962</ArticleId></ArticleIdList></Reference><Reference><Citation>Bottcher C, Schlickeiser S, Sneeboer MAM, Kunkel D, Knop A, Paza E, Fidzinski P, Kraus L, Snijders GJL, Kahn RS, et al. Human microglia regional heterogeneity and phenotypes determined by multiplexed single-cell mass cytometry. Nat Neurosci. 2019;22:78&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">30559476</ArticleId></ArticleIdList></Reference><Reference><Citation>Grabert K, Michoel T, Karavolos MH, Clohisey S, Baillie JK, Stevens MP, Freeman TC, Summers KM, McColl BW. Microglial brain region-dependent diversity and selective regional sensitivities to aging. Nat Neurosci. 2016;19:504&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4768346</ArticleId><ArticleId IdType="pubmed">26780511</ArticleId></ArticleIdList></Reference><Reference><Citation>Jordao MJC, Sankowski R, Brendecke SM, Sagar LG, Tai YH, Tay TL, Schramm E, Armbruster S, Hagemeyer N, et al. Single-cell profiling identifies myeloid cell subsets with distinct fates during neuroinflammation. Science. 2019;363(6425):eaat7554.</Citation><ArticleIdList><ArticleId IdType="pubmed">30679343</ArticleId></ArticleIdList></Reference><Reference><Citation>Ajami B, Samusik N, Wieghofer P, Ho PP, Crotti A, Bjornson Z, Prinz M, Fantl WJ, Nolan GP, Steinman L. Single-cell mass cytometry reveals distinct populations of brain myeloid cells in mouse neuroinflammation and neurodegeneration models. Nat Neurosci. 2018;21:541&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pubmed">29507414</ArticleId></ArticleIdList></Reference><Reference><Citation>Stratoulias V, Venero JL, Tremblay ME, Joseph B. Microglial subtypes: diversity within the microglial community. EMBO J. 2019;38:e101997.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6717890</ArticleId><ArticleId IdType="pubmed">31373067</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff RM. A polarizing question: do M1 and M2 microglia exist? Nat Neurosci. 2016;19:987&#x2013;991.</Citation><ArticleIdList><ArticleId IdType="pubmed">27459405</ArticleId></ArticleIdList></Reference><Reference><Citation>Labzin LI, Heneka MT, Latz E. Innate Immunity and Neurodegeneration. Annu Rev Med. 2018;69:437&#x2013;449.</Citation><ArticleIdList><ArticleId IdType="pubmed">29106805</ArticleId></ArticleIdList></Reference><Reference><Citation>Pacheco R. Cross-talk between T-cells and gut-microbiota in neurodegenerative disorders. Neural Regen Res. 2019;14:2091&#x2013;2092.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6788236</ArticleId><ArticleId IdType="pubmed">31397345</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Q, Xing C, Long W, Wang HY, Liu Q, Wang RF. Impact of microbiota on central nervous system and neurological diseases: the gut-brain axis. J Neuroinflammation. 2019;16:53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6397457</ArticleId><ArticleId IdType="pubmed">30823925</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampson TR, Debelius JW, Thron T, Janssen S, Shastri GG, Ilhan ZE, Challis C, Schretter CE, Rocha S, Gradinaru V, et al. Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease. Cell. 2016;167:1469&#x2013;1480.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5718049</ArticleId><ArticleId IdType="pubmed">27912057</ArticleId></ArticleIdList></Reference><Reference><Citation>Berer K, Gerdes LA, Cekanaviciute E, Jia X, Xiao L, Xia Z, Liu C, Klotz L, Stauffer U, Baranzini SE, et al. Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice. Proc Natl Acad Sci U S A. 2017;114:10719&#x2013;10724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5635914</ArticleId><ArticleId IdType="pubmed">28893994</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhuang ZQ, Shen LL, Li WW, Fu X, Zeng F, Gui L, Lu Y, Cai M, Zhu C, Tan YL, et al. Gut Microbiota is Altered in Patients with Alzheimer's Disease. J Alzheimers Dis. 2018;63:1337&#x2013;1346.</Citation><ArticleIdList><ArticleId IdType="pubmed">29758946</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauerl C, Collado MC, Diaz Cuevas A, Vina J, Perez Martinez G. Shifts in gut microbiota composition in an APP/PSS1 transgenic mouse model of Alzheimer's disease during lifespan. Lett Appl Microbiol. 2018;66:464&#x2013;471.</Citation><ArticleIdList><ArticleId IdType="pubmed">29575030</ArticleId></ArticleIdList></Reference><Reference><Citation>Harach T, Marungruang N, Duthilleul N, Cheatham V, Mc Coy KD, Frisoni G, Neher JJ, Fak F, Jucker M, Lasser T, Bolmont T. Reduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota. Sci Rep. 2017;7:41802.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5297247</ArticleId><ArticleId IdType="pubmed">28176819</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi JG, Kim N, Ju IG, Eo H, Lim SM, Jang SE, Kim DH, Oh MS. Oral administration of Proteus mirabilis damages dopaminergic neurons and motor functions in mice. Sci Rep. 2018;8:1275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5775305</ArticleId><ArticleId IdType="pubmed">29352191</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YG, Wu S, Yi J, Xia Y, Jin D, Zhou J, Sun J. Target Intestinal Microbiota to Alleviate Disease Progression in Amyotrophic Lateral Sclerosis. Clin Ther. 2017;39:322&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5344195</ArticleId><ArticleId IdType="pubmed">28129947</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Wang F, Liu S, Du J, Hu X, Xiong J, Fang R, Chen W, Sun J. Sodium butyrate exerts protective effect against Parkinson's disease in mice via stimulation of glucagon like peptide-1. J Neurol Sci. 2017;381:176&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">28991675</ArticleId></ArticleIdList></Reference><Reference><Citation>Srivastav S, Neupane S, Bhurtel S, Katila N, Maharjan S, Choi H, Hong JT, Choi DY. Probiotics mixture increases butyrate, and subsequently rescues the nigral dopaminergic neurons from MPTP and rotenone-induced neurotoxicity. J Nutr Biochem. 2019;69:73&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">31063918</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivanov II, Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U, Wei D, Goldfarb KC, Santee CA, Lynch SV, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell. 2009;139:485&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796826</ArticleId><ArticleId IdType="pubmed">19836068</ArticleId></ArticleIdList></Reference><Reference><Citation>Round JL, Mazmanian SK. Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc Natl Acad Sci U S A. 2010;107:12204&#x2013;12209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2901479</ArticleId><ArticleId IdType="pubmed">20566854</ArticleId></ArticleIdList></Reference><Reference><Citation>Arpaia N, Campbell C, Fan X. Dikiy S, van der Veeken J, deRoos P, Liu H, Cross JR, Pfeffer K, Coffer PJ, Rudensky AY: Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature. 2013;504:451&#x2013;455.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3869884</ArticleId><ArticleId IdType="pubmed">24226773</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez H, Contreras F, Pacheco R. Regulation of the Neurodegenerative Process Associated to Parkinson's Disease by CD4+ T-cells. J Neuroimmune Pharmacol. 2015;10:561&#x2013;575.</Citation><ArticleIdList><ArticleId IdType="pubmed">26018603</ArticleId></ArticleIdList></Reference><Reference><Citation>Campos-Acuna J, Elgueta D, Pacheco R. T-Cell-Driven Inflammation as a Mediator of the Gut-Brain Axis Involved in Parkinson's Disease. Front Immunol. 2019;10:239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6384270</ArticleId><ArticleId IdType="pubmed">30828335</ArticleId></ArticleIdList></Reference><Reference><Citation>Fung TC, Olson CA, Hsiao EY. Interactions between the microbiota, immune and nervous systems in health and disease. Nat Neurosci. 2017;20:145&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6960010</ArticleId><ArticleId IdType="pubmed">28092661</ArticleId></ArticleIdList></Reference><Reference><Citation>Erny D. Hrabe de Angelis AL, Jaitin D, Wieghofer P, Staszewski O, David E, Keren-Shaul H, Mahlakoiv T, Jakobshagen K, Buch T, et al: Host microbiota constantly control maturation and function of microglia in the CNS. Nat Neurosci. 2015;18:965&#x2013;977.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5528863</ArticleId><ArticleId IdType="pubmed">26030851</ArticleId></ArticleIdList></Reference><Reference><Citation>Matcovitch-Natan O, Winter DR, Giladi A, Vargas Aguilar S, Spinrad A, Sarrazin S, Ben-Yehuda H, David E, Zelada Gonzalez F, Perrin P, et al. Microglia development follows a stepwise program to regulate brain homeostasis. Science. 2016;353:aad8670.</Citation><ArticleIdList><ArticleId IdType="pubmed">27338705</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson NS, El-Sukkari D, Villadangos JA. Dendritic cells constitutively present self antigens in their immature state in vivo and regulate antigen presentation by controlling the rates of MHC class II synthesis and endocytosis. Blood. 2004;103:2187&#x2013;2195.</Citation><ArticleIdList><ArticleId IdType="pubmed">14604956</ArticleId></ArticleIdList></Reference><Reference><Citation>Raker VK, Domogalla MP, Steinbrink K. Tolerogenic Dendritic Cells for Regulatory T Cell Induction in Man. Front Immunol. 2015;6:569.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4638142</ArticleId><ArticleId IdType="pubmed">26617604</ArticleId></ArticleIdList></Reference><Reference><Citation>Domogalla MP, Rostan PV, Raker VK, Steinbrink K. Tolerance through Education: How Tolerogenic Dendritic Cells Shape Immunity. Front Immunol. 2017;8:1764.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5770648</ArticleId><ArticleId IdType="pubmed">29375543</ArticleId></ArticleIdList></Reference><Reference><Citation>Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pubmed">9521319</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanoni I, Granucci F. Regulation of antigen uptake, migration, and lifespan of dendritic cell by Toll-like receptors. J Mol Med (Berl) 2010;88:873&#x2013;880.</Citation><ArticleIdList><ArticleId IdType="pubmed">20556351</ArticleId></ArticleIdList></Reference><Reference><Citation>Malissen B, Gregoire C, Malissen M, Roncagalli R. Integrative biology of T cell activation. Nat Immunol. 2014;15:790&#x2013;797.</Citation><ArticleIdList><ArticleId IdType="pubmed">25137453</ArticleId></ArticleIdList></Reference><Reference><Citation>Drutman SB, Trombetta ES. Dendritic cells continue to capture and present antigens after maturation in vivo. J Immunol. 2010;185:2140&#x2013;2146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2928255</ArticleId><ArticleId IdType="pubmed">20644175</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinbrink K, Graulich E, Kubsch S, Knop J, Enk AH. CD4(+) and CD8(+) anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity. Blood. 2002;99:2468&#x2013;2476.</Citation><ArticleIdList><ArticleId IdType="pubmed">11895781</ArticleId></ArticleIdList></Reference><Reference><Citation>Kryczanowsky F, Raker V, Graulich E, Domogalla MP, Steinbrink K. IL-10-modulated human dendritic cells for clinical use: identification of a stable and migratory subset with improved tolerogenic activity. J Immunol. 2016;197:3607&#x2013;3617.</Citation><ArticleIdList><ArticleId IdType="pubmed">27683749</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Cao X. Regulatory dendritic cells in autoimmunity: A comprehensive review. J Autoimmun. 2015;63:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">26255250</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Rey E, Chorny A, Fernandez-Martin A, Ganea D, Delgado M. Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells. Blood. 2006;107:3632&#x2013;3638.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1895772</ArticleId><ArticleId IdType="pubmed">16397128</ArticleId></ArticleIdList></Reference><Reference><Citation>Schutt CR, Gendelman HE, Mosley RL. Tolerogenic bone marrow-derived dendritic cells induce neuroprotective regulatory T cells in a model of Parkinson's disease. Mol Neurodegener. 2018;13:26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5963189</ArticleId><ArticleId IdType="pubmed">29783988</ArticleId></ArticleIdList></Reference><Reference><Citation>Olivar R, Luque A, Cardenas-Brito S, Naranjo-Gomez M, Blom AM, Borras FE. Rodriguez de Cordoba S, Zipfel PF, Aran JM: The Complement Inhibitor Factor H Generates an Anti-Inflammatory and Tolerogenic State in Monocyte-Derived Dendritic Cells. J Immunol. 2016;196:4274&#x2013;4290.</Citation><ArticleIdList><ArticleId IdType="pubmed">27076676</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira GB, Vanherwegen AS, Eelen G, Gutierrez ACF, Van Lommel L, Marchal K, Verlinden L, Verstuyf A, Nogueira T, Georgiadou M, et al. Vitamin D3 Induces Tolerance in Human Dendritic Cells by Activation of Intracellular Metabolic Pathways. Cell Rep. 2015;10:711&#x2013;725.</Citation><ArticleIdList><ArticleId IdType="pubmed">25660022</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutella S, Bonanno G, Procoli A, Mariotti A, de Ritis DG, Curti A, Danese S, Pessina G, Pandolfi S, Natoni F, et al. Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features. Blood. 2006;108:218&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">16527888</ArticleId></ArticleIdList></Reference><Reference><Citation>Duffy SS, Keating BA, Perera CJ, Moalem-Taylor G. The role of regulatory T cells in nervous system pathologies. J Neurosci Res. 2018;96:951&#x2013;968.</Citation><ArticleIdList><ArticleId IdType="pubmed">28488363</ArticleId></ArticleIdList></Reference><Reference><Citation>Mount MP, Lira A, Grimes D, Smith PD, Faucher S, Slack R, Anisman H, Hayley S, Park DS. Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons. J Neurosci. 2007;27:3328&#x2013;3337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672486</ArticleId><ArticleId IdType="pubmed">17376993</ArticleId></ArticleIdList></Reference><Reference><Citation>Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R, Bernard M, Giuliani F, Arbour N, Becher B, Prat A. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med. 2007;13:1173&#x2013;1175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5114125</ArticleId><ArticleId IdType="pubmed">17828272</ArticleId></ArticleIdList></Reference><Reference><Citation>Grebing M, Nielsen HH, Fenger CD, TJ K, von Linstow CU, Clausen BH, Soderman M, Lambertsen KL, Thomassen M, Kruse TA, Finsen B. Myelin-specific T cells induce interleukin-1beta expression in lesion-reactive microglial-like cells in zones of axonal degeneration. Glia. 2016;64:407&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pubmed">26496662</ArticleId></ArticleIdList></Reference><Reference><Citation>Depboylu C, Stricker S, Ghobril JP, Oertel WH, Priller J, Hoglinger GU. Brain-resident microglia predominate over infiltrating myeloid cells in activation, phagocytosis and interaction with T-lymphocytes in the MPTP mouse model of Parkinson disease. Exp Neurol. 2012;238:183&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">22964486</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J, Luber-Narod J, Styren SD, Civin WH. Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease. Neurobiol Aging. 1988;9:339&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">3263583</ArticleId></ArticleIdList></Reference><Reference><Citation>Parachikova A, Agadjanyan MG, Cribbs DH, Blurton-Jones M, Perreau V, Rogers J, Beach TG, Cotman CW. Inflammatory changes parallel the early stages of Alzheimer disease. Neurobiol Aging. 2007;28:1821&#x2013;1833.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2198930</ArticleId><ArticleId IdType="pubmed">17052803</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong Y, Benveniste EN. Immune function of astrocytes. Glia. 2001;36:180&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">11596126</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie L, Yang SH. Interaction of astrocytes and T cells in physiological and pathological conditions. Brain Res. 1623;2015:63&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4569510</ArticleId><ArticleId IdType="pubmed">25813828</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan L, Gordon KB, Mueller JP, Matis LA, Miller SD. Presentation of proteolipid protein epitopes and B7&#x2013;1-dependent activation of encephalitogenic T cells by IFN-gamma-activated SJL/J astrocytes. J Immunol. 1998;160:4271&#x2013;4279.</Citation><ArticleIdList><ArticleId IdType="pubmed">9574529</ArticleId></ArticleIdList></Reference><Reference><Citation>Soos JM, Ashley TA, Morrow J, Patarroyo JC, Szente BE, Zamvil SS. Differential expression of B7 co-stimulatory molecules by astrocytes correlates with T cell activation and cytokine production. Int Immunol. 1999;11:1169&#x2013;1179.</Citation><ArticleIdList><ArticleId IdType="pubmed">10383950</ArticleId></ArticleIdList></Reference><Reference><Citation>Bechmann I, Steiner B, Gimsa U, Mor G, Wolf S, Beyer M, Nitsch R, Zipp F. Astrocyte-induced T cell elimination is CD95 ligand dependent. J Neuroimmunol. 2002;132:60&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">12417434</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M, McGeer E, McGeer PL. Neurotoxins released from interferon-gamma-stimulated human astrocytes. Neuroscience. 2013;229:164&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pubmed">23098801</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Sonobe Y, Akahori T, Jin S, Kawanokuchi J, Noda M, Iwakura Y, Mizuno T, Suzumura A. IL-9 promotes Th17 cell migration into the central nervous system via CC chemokine ligand-20 produced by astrocytes. J Immunol. 2011;186:4415&#x2013;4421.</Citation><ArticleIdList><ArticleId IdType="pubmed">21346235</ArticleId></ArticleIdList></Reference><Reference><Citation>Giuliani F, Goodyer CG, Antel JP, Yong VW. Vulnerability of human neurons to T cell-mediated cytotoxicity. J Immunol. 2003;171:368&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pubmed">12817020</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Huang Y, Cao BB, Qiu YH, Peng YP. Th17 Cells Induce Dopaminergic Neuronal Death via LFA-1/ICAM-1 Interaction in a Mouse Model of Parkinson's Disease. Mol Neurobiol. 2017;54:7762&#x2013;7776.</Citation><ArticleIdList><ArticleId IdType="pubmed">27844285</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowther DE, Hafler DA. Regulatory T cells in the central nervous system. Immunol Rev. 2012;248:156&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">22725960</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie L, Choudhury GR, Winters A, Yang SH, Jin K. Cerebral regulatory T cells restrain microglia/macrophage-mediated inflammatory responses via IL-10. Eur J Immunol. 2015;45:180&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4293323</ArticleId><ArticleId IdType="pubmed">25329858</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders JA, Estes KA, Kosloski LM, Allen HE, Dempsey KM, Torres-Russotto DR, Meza JL, Santamaria PM, Bertoni JM, Murman DL, et al. CD4+ regulatory and effector/memory T cell subsets profile motor dysfunction in Parkinson's disease. J Neuroimmune Pharmacol. 2012;7:927&#x2013;938.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3515774</ArticleId><ArticleId IdType="pubmed">23054369</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito M, Komai K, Mise-Omata S, Iizuka-Koga M, Noguchi Y, Kondo T, Sakai R, Matsuo K, Nakayama T, Yoshie O, et al. Brain regulatory T cells suppress astrogliosis and potentiate neurological recovery. Nature. 2019;565:246&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">30602786</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Liu Z, Cao BB, Qiu YH, Peng YP. Treg Cells Protect Dopaminergic Neurons against MPP+ Neurotoxicity via CD47-SIRPA Interaction. Cell Physiol Biochem. 2017;41:1240&#x2013;1254.</Citation><ArticleIdList><ArticleId IdType="pubmed">28268219</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber RD. Michigan's Malpractice Reform Legislation: what you need to know. J Mich Dent Assoc. 1993;75:38&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">8040859</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P, Wang L, Zhou Y, Gan Y, Zhu W, Xia Y, Jiang X, Watkins S, Vazquez A, Thomson AW, et al. C-C Chemokine Receptor Type 5 (CCR5)-Mediated Docking of Transferred Tregs Protects Against Early Blood-Brain Barrier Disruption After Stroke. J Am Heart Assoc. 2017;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5586468</ArticleId><ArticleId IdType="pubmed">28768648</ArticleId></ArticleIdList></Reference><Reference><Citation>Deliyanti D, Talia DM, Zhu T, Maxwell MJ, Agrotis A, Jerome JR, Hargreaves EM, Gerondakis S, Hibbs ML, Mackay F, Wilkinson-Berka JL. Foxp3(+) Tregs are recruited to the retina to repair pathological angiogenesis. Nat Commun. 2017;8:748.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5622066</ArticleId><ArticleId IdType="pubmed">28963474</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandolfo MT, Jang HR, Bagnasco SM, Ko GJ, Agreda P, Satpute SR, Crow MT, King LS, Rabb H. Foxp3+ regulatory T cells participate in repair of ischemic acute kidney injury. Kidney Int. 2009;76:717&#x2013;729.</Citation><ArticleIdList><ArticleId IdType="pubmed">19625990</ArticleId></ArticleIdList></Reference><Reference><Citation>Haertel E, Joshi N, Hiebert P, Kopf M, Werner S. Regulatory T cells are required for normal and activin-promoted wound repair in mice. Eur J Immunol. 2018;48:1001&#x2013;1013.</Citation><ArticleIdList><ArticleId IdType="pubmed">29457218</ArticleId></ArticleIdList></Reference><Reference><Citation>Togo T, Akiyama H, Iseki E, Kondo H, Ikeda K, Kato M, Oda T, Tsuchiya K, Kosaka K. Occurrence of T cells in the brain of Alzheimer's disease and other neurological diseases. J Neuroimmunol. 2002;124:83&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">11958825</ArticleId></ArticleIdList></Reference><Reference><Citation>Bielekova B, Goodwin B, Richert N, Cortese I, Kondo T, Afshar G, Gran B, Eaton J, Antel J, Frank JA, et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83&#x2013;99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med. 2000;6:1167&#x2013;1175.</Citation><ArticleIdList><ArticleId IdType="pubmed">11017150</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciccarelli O, Barkhof F, Bodini B, De Stefano N, Golay X, Nicolay K, Pelletier D, Pouwels PJ, Smith SA, Wheeler-Kingshott CA, et al. Pathogenesis of multiple sclerosis: insights from molecular and metabolic imaging. Lancet Neurol. 2014;13:807&#x2013;822.</Citation><ArticleIdList><ArticleId IdType="pubmed">25008549</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou YK, Bourdette DN, Offner H, Whitham R, Wang RY, Hashim GA, Vandenbark AA. Frequency of T cells specific for myelin basic protein and myelin proteolipid protein in blood and cerebrospinal fluid in multiple sclerosis. J Neuroimmunol. 1992;38:105&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">1374422</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Markovic-Plese S, Lacet B, Raus J, Weiner HL, Hafler DA. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med. 1994;179:973&#x2013;984.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2191414</ArticleId><ArticleId IdType="pubmed">7509366</ArticleId></ArticleIdList></Reference><Reference><Citation>Kebir H, Ifergan I, Alvarez JI, Bernard M, Poirier J, Arbour N, Duquette P, Prat A. Preferential recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis. Ann Neurol. 2009;66:390&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">19810097</ArticleId></ArticleIdList></Reference><Reference><Citation>Stromnes IM, Goverman JM. Active induction of experimental allergic encephalomyelitis. Nat Protoc. 2006;1:1810&#x2013;1819.</Citation><ArticleIdList><ArticleId IdType="pubmed">17487163</ArticleId></ArticleIdList></Reference><Reference><Citation>Stromnes IM, Goverman JM. Passive induction of experimental allergic encephalomyelitis. Nat Protoc. 2006;1:1952&#x2013;1960.</Citation><ArticleIdList><ArticleId IdType="pubmed">17487182</ArticleId></ArticleIdList></Reference><Reference><Citation>Glabinski AR, Tani M, Tuohy VK, Ransohoff RM. Murine experimental autoimmune encephalomyelitis: a model of immune-mediated inflammation and multiple sclerosis. Methods Enzymol. 1997;288:182&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">9356995</ArticleId></ArticleIdList></Reference><Reference><Citation>Jager A, Dardalhon V, Sobel RA, Bettelli E, Kuchroo VK. Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J Immunol. 2009;183:7169&#x2013;7177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2921715</ArticleId><ArticleId IdType="pubmed">19890056</ArticleId></ArticleIdList></Reference><Reference><Citation>Domingues HS, Mues M, Lassmann H, Wekerle H, Krishnamoorthy G. Functional and pathogenic differences of Th1 and Th17 cells in experimental autoimmune encephalomyelitis. PLoS One. 2010;5:e15531.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3000428</ArticleId><ArticleId IdType="pubmed">21209700</ArticleId></ArticleIdList></Reference><Reference><Citation>Axtell RC, de Jong BA, Boniface K, van der Voort LF, Bhat R, De Sarno P, Naves R, Han M, Zhong F, Castellanos JG, et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med. 2010;16:406&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3042885</ArticleId><ArticleId IdType="pubmed">20348925</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierson E, Simmons SB, Castelli L, Goverman JM. Mechanisms regulating regional localization of inflammation during CNS autoimmunity. Immunol Rev. 2012;248:205&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3678350</ArticleId><ArticleId IdType="pubmed">22725963</ArticleId></ArticleIdList></Reference><Reference><Citation>Danikowski KM, Jayaraman S, Prabhakar BS. Regulatory T cells in multiple sclerosis and myasthenia gravis. J Neuroinflammation. 2017;14:117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5466736</ArticleId><ArticleId IdType="pubmed">28599652</ArticleId></ArticleIdList></Reference><Reference><Citation>Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med. 2004;199:971&#x2013;979.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2211881</ArticleId><ArticleId IdType="pubmed">15067033</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YF, Zhang SX, Ma XW, Xue YL, Gao C, Li XY, Xu AD. The proportion of peripheral regulatory T cells in patients with Multiple Sclerosis: A meta-analysis. Mult Scler Relat Disord. 2019;28:75&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">30572285</ArticleId></ArticleIdList></Reference><Reference><Citation>Sloane E, Ledeboer A, Seibert W, Coats B, van Strien M, Maier SF, Johnson KW, Chavez R, Watkins LR, Leinwand L, et al. Anti-inflammatory cytokine gene therapy decreases sensory and motor dysfunction in experimental Multiple Sclerosis: MOG-EAE behavioral and anatomical symptom treatment with cytokine gene therapy. Brain Behav Immun. 2009;23:92&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2631931</ArticleId><ArticleId IdType="pubmed">18835435</ArticleId></ArticleIdList></Reference><Reference><Citation>Ephrem A, Chamat S, Miquel C, Fisson S, Mouthon L, Caligiuri G, Delignat S, Elluru S, Bayry J, Lacroix-Desmazes S, et al. Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood. 2008;111:715&#x2013;722.</Citation><ArticleIdList><ArticleId IdType="pubmed">17932250</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Martin A, Gonzalez-Rey E, Chorny A, Ganea D, Delgado M. Vasoactive intestinal peptide induces regulatory T cells during experimental autoimmune encephalomyelitis. Eur J Immunol. 2006;36:318&#x2013;326.</Citation><ArticleIdList><ArticleId IdType="pubmed">16402407</ArticleId></ArticleIdList></Reference><Reference><Citation>Serpero LD, Filaci G, Parodi A, Battaglia F, Kalli F, Brogi D, Mancardi GL, Uccelli A, Fenoglio D. Fingolimod modulates peripheral effector and regulatory T cells in MS patients. J Neuroimmune Pharmacol. 2013;8:1106&#x2013;1113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3889247</ArticleId><ArticleId IdType="pubmed">23649711</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez-Villar M, Raddassi K, Danielsen AC, Guarnaccia J, Hafler DA. Fingolimod modulates T cell phenotype and regulatory T cell plasticity in vivo. J Autoimmun. 2019;96:40&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">30122421</ArticleId></ArticleIdList></Reference><Reference><Citation>Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013;9:63&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">23305823</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellani RJ, Rolston RK, Smith MA. Alzheimer disease. Dis Mon. 2010;56:484&#x2013;546.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2941917</ArticleId><ArticleId IdType="pubmed">20831921</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">10408445</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med. 2003;9:448&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">12640446</ArticleId></ArticleIdList></Reference><Reference><Citation>Monsonego A, Imitola J, Petrovic S, Zota V, Nemirovsky A, Baron R, Fisher Y, Owens T, Weiner HL. Abeta-induced meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2006;103:5048&#x2013;5053.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1458792</ArticleId><ArticleId IdType="pubmed">16549802</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao C, Arendash GW, Dickson A, Mamcarz MB, Lin X, Ethell DW. Abeta-specific Th2 cells provide cognitive and pathological benefits to Alzheimer's mice without infiltrating the CNS. Neurobiol Dis. 2009;34:63&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5546306</ArticleId><ArticleId IdType="pubmed">19167499</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi B, Angiari S, Zenaro E, Budui SL, Constantin G. Vascular inflammation in central nervous system diseases: adhesion receptors controlling leukocyte-endothelial interactions. J Leukoc Biol. 2011;89:539&#x2013;556.</Citation><ArticleIdList><ArticleId IdType="pubmed">21169520</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferretti MT, Merlini M, Spani C, Gericke C, Schweizer N, Enzmann G, Engelhardt B, Kulic L, Suter T, Nitsch RM. T-cell brain infiltration and immature antigen-presenting cells in transgenic models of Alzheimer's disease-like cerebral amyloidosis. Brain Behav Immun. 2016;54:211&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pubmed">26872418</ArticleId></ArticleIdList></Reference><Reference><Citation>McManus RM, Higgins SC, Mills KH, Lynch MA. Respiratory infection promotes T cell infiltration and amyloid-beta deposition in APP/PS1 mice. Neurobiol Aging. 2014;35:109&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pubmed">23993702</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu XL, Yao XQ, Jiao SS, Zeng F, Liu YH, Xiang Y, Liang CR, Wang QH, Wang X, Cao HY, et al. A study on the association between infectious burden and Alzheimer's disease. Eur J Neurol. 2015;22:1519&#x2013;1525.</Citation><ArticleIdList><ArticleId IdType="pubmed">24910016</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim SL, Rodriguez-Ortiz CJ, Kitazawa M. Infection, systemic inflammation, and Alzheimer's disease. Microbes Infect. 2015;17:549&#x2013;556.</Citation><ArticleIdList><ArticleId IdType="pubmed">25912134</ArticleId></ArticleIdList></Reference><Reference><Citation>Strandberg TE, Pitkala KH, Linnavuori KH, Tilvis RS. Impact of viral and bacterial burden on cognitive impairment in elderly persons with cardiovascular diseases. Stroke. 2003;34:2126&#x2013;2131.</Citation><ArticleIdList><ArticleId IdType="pubmed">12920256</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Wang YJ, Zhang M, Xu ZQ, Gao CY, Fang CQ, Yan JC, Zhou HD. Chongqing Ageing Study G: Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease. Neurology. 2011;76:1485&#x2013;1491.</Citation><ArticleIdList><ArticleId IdType="pubmed">21490316</ArticleId></ArticleIdList></Reference><Reference><Citation>Browne TC, McQuillan K, McManus RM, O'Reilly JA, Mills KH, Lynch MA. IFN-gamma Production by amyloid beta-specific Th1 cells promotes microglial activation and increases plaque burden in a mouse model of Alzheimer's disease. J Immunol. 2013;190:2241&#x2013;2251.</Citation><ArticleIdList><ArticleId IdType="pubmed">23365075</ArticleId></ArticleIdList></Reference><Reference><Citation>Gate D, Saligrama N, Leventhal O, Yang AC, Unger MS, Middeldorp J, Chen K, Lehallier B, Channappa D, De Los Santos MB, et al. Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer's disease. Nature. 2020;577:399&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7445078</ArticleId><ArticleId IdType="pubmed">31915375</ArticleId></ArticleIdList></Reference><Reference><Citation>Lueg G, Gross CC, Lohmann H, Johnen A, Kemmling A, Deppe M, Groger J, Minnerup J, Wiendl H, Meuth SG, Duning T. Clinical relevance of specific T-cell activation in the blood and cerebrospinal fluid of patients with mild Alzheimer's disease. Neurobiol Aging. 2015;36:81&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">25277040</ArticleId></ArticleIdList></Reference><Reference><Citation>Merlini M, Kirabali T, Kulic L, Nitsch RM, Ferretti MT. Extravascular CD3+ T Cells in Brains of Alzheimer Disease Patients Correlate with Tau but Not with Amyloid Pathology: An Immunohistochemical Study. Neurodegener Dis. 2018;18:49&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">29402847</ArticleId></ArticleIdList></Reference><Reference><Citation>Saresella M, Calabrese E, Marventano I, Piancone F, Gatti A, Alberoni M, Nemni R, Clerici M. Increased activity of Th-17 and Th-9 lymphocytes and a skewing of the post-thymic differentiation pathway are seen in Alzheimer's disease. Brain Behav Immun. 2011;25:539&#x2013;547.</Citation><ArticleIdList><ArticleId IdType="pubmed">21167930</ArticleId></ArticleIdList></Reference><Reference><Citation>Agnes P, Christiane S, Peter D. T-cells show increased production of cytokines and activation markers in Alzheimer&#x2019;s disease. Brain Disord Ther. 2013;3:3&#x2013;112.</Citation></Reference><Reference><Citation>Heneka MT, O'Banion MK, Terwel D, Kummer MP. Neuroinflammatory processes in Alzheimer's disease. J Neural Transm (Vienna) 2010;117:919&#x2013;947.</Citation><ArticleIdList><ArticleId IdType="pubmed">20632195</ArticleId></ArticleIdList></Reference><Reference><Citation>Chui R, Dorovini-Zis K. Regulation of CCL2 and CCL3 expression in human brain endothelial cells by cytokines and lipopolysaccharide. J Neuroinflammation. 2010;7:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819252</ArticleId><ArticleId IdType="pubmed">20047691</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberstein TJ, Taha L, Spitzer P, Hellstern J, Herrmann M, Kornhuber J, Maler JM. Imbalance of Circulating Th17 and Regulatory T Cells in Alzheimer's Disease: A Case Control Study. Front Immunol. 2018;9:1213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5994416</ArticleId><ArticleId IdType="pubmed">29915582</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Ke KF, Liu Z, Qiu YH, Peng YP. Th17 cell-mediated neuroinflammation is involved in neurodegeneration of abeta1&#x2013;42-induced Alzheimer's disease model rats. PLoS One. 2013;8:e75786.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3790825</ArticleId><ArticleId IdType="pubmed">24124514</ArticleId></ArticleIdList></Reference><Reference><Citation>Larbi A, Pawelec G, Witkowski JM, Schipper HM, Derhovanessian E, Goldeck D, Fulop T. Dramatic shifts in circulating CD4 but not CD8 T cell subsets in mild Alzheimer's disease. J Alzheimers Dis. 2009;17:91&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">19494434</ArticleId></ArticleIdList></Reference><Reference><Citation>Avidan H, Kipnis J, Butovsky O, Caspi RR, Schwartz M. Vaccination with autoantigen protects against aggregated beta-amyloid and glutamate toxicity by controlling microglia: effect of CD4+CD25+ T cells. Eur J Immunol. 2004;34:3434&#x2013;3445.</Citation><ArticleIdList><ArticleId IdType="pubmed">15549735</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenkranz D, Weyer S, Tolosa E, Gaenslen A, Berg D, Leyhe T, Gasser T, Stoltze L. Higher frequency of regulatory T cells in the elderly and increased suppressive activity in neurodegeneration. J Neuroimmunol. 2007;188:117&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">17582512</ArticleId></ArticleIdList></Reference><Reference><Citation>Baruch K, Rosenzweig N, Kertser A, Deczkowska A, Sharif AM, Spinrad A, Tsitsou-Kampeli A, Sarel A, Cahalon L, Schwartz M. Breaking immune tolerance by targeting Foxp3(+) regulatory T cells mitigates Alzheimer's disease pathology. Nat Commun. 2015;6:7967.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4557123</ArticleId><ArticleId IdType="pubmed">26284939</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciccocioppo F, Lanuti P, Pierdomenico L, Simeone P, Bologna G, Ercolino E, Buttari F, Fantozzi R, Thomas A, Onofrj M, et al. The Characterization of Regulatory T-Cell Profiles in Alzheimer's Disease and Multiple Sclerosis. Sci Rep. 2019;9:8788.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6584558</ArticleId><ArticleId IdType="pubmed">31217537</ArticleId></ArticleIdList></Reference><Reference><Citation>Dansokho C, Ait Ahmed D, Aid S, Toly-Ndour C, Chaigneau T, Calle V, Cagnard N, Holzenberger M, Piaggio E, Aucouturier P, Dorothee G. Regulatory T cells delay disease progression in Alzheimer-like pathology. Brain. 2016;139:1237&#x2013;1251.</Citation><ArticleIdList><ArticleId IdType="pubmed">26912648</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H, Yang H, Xie Z, Wei L, Bi J. Systemic transplantation of human umbilical cord derived mesenchymal stem cells-educated T regulatory cells improved the impaired cognition in AbetaPPswe/PS1dE9 transgenic mice. PLoS One. 2013;8:e69129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3723739</ArticleId><ArticleId IdType="pubmed">23935936</ArticleId></ArticleIdList></Reference><Reference><Citation>Alves S, Churlaud G, Audrain M, Michaelsen-Preusse K, Fol R, Souchet B, Braudeau J, Korte M, Klatzmann D, Cartier N. Interleukin-2 improves amyloid pathology, synaptic failure and memory in Alzheimer's disease mice. Brain. 2017;140:826&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pubmed">28003243</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye M, Chung HS, Lee C, Yoon MS, Yu AR, Kim JS, Hwang DS, Shim I, Bae H. Neuroprotective effects of bee venom phospholipase A2 in the 3xTg AD mouse model of Alzheimer's disease. J Neuroinflammation. 2016;13:10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4715334</ArticleId><ArticleId IdType="pubmed">26772975</ArticleId></ArticleIdList></Reference><Reference><Citation>Aytan N, Choi JK, Carreras I, Brinkmann V, Kowall NW, Jenkins BG, Dedeoglu A. Fingolimod modulates multiple neuroinflammatory markers in a mouse model of Alzheimer's disease. Sci Rep. 2016;6:24939.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4847010</ArticleId><ArticleId IdType="pubmed">27117087</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao C, Qian Y, Huang J, Wang D, Su W, Wang P, Guo L, Quan W, An S, Zhang J, Jiang R. A Three-Day Consecutive Fingolimod Administration Improves Neurological Functions and Modulates Multiple Immune Responses of CCI Mice. Mol Neurobiol. 2017;54:8348&#x2013;8360.</Citation><ArticleIdList><ArticleId IdType="pubmed">27924525</ArticleId></ArticleIdList></Reference><Reference><Citation>Potter H, Woodcock JH, Boyd T, Sillau SH, Bettcher BM, Daniels J, Heffernan KS, Gray H. Interim report of a phase 2 pilot safety and efficacy trial of gm-csf/leukine&lt;sup&gt;&#xae;&lt;/sup&gt; in mild-to-moderate alzheimer's diseasE. Alzheimer's &amp; Dementia: J Alzheimer's Assoc. 2017;13:P1572.</Citation></Reference><Reference><Citation>Kurkowska-Jastrzebska I, Wronska A, Kohutnicka M, Czlonkowski A, Czlonkowska A. The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse. Exp Neurol. 1999;156:50&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">10192776</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Qi B, Xu W, Ma B, Li L, Chen Q, Qian W, Liu X, Qu H. Clinical correlation of peripheral CD4+cell subsets, their imbalance and Parkinson's disease. Mol Med Rep. 2015;12:6105&#x2013;6111.</Citation><ArticleIdList><ArticleId IdType="pubmed">26239429</ArticleId></ArticleIdList></Reference><Reference><Citation>Kustrimovic N, Comi C, Magistrelli L, Rasini E, Legnaro M, Bombelli R, Aleksic I, Blandini F, Minafra B, Riboldazzi G, et al. Parkinson's disease patients have a complex phenotypic and functional Th1 bias: cross-sectional studies of CD4+ Th1/Th2/T17 and Treg in drug-naive and drug-treated patients. J Neuroinflammation. 2018;15:205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6044047</ArticleId><ArticleId IdType="pubmed">30001736</ArticleId></ArticleIdList></Reference><Reference><Citation>Baba Y, Kuroiwa A, Uitti RJ, Wszolek ZK, Yamada T. Alterations of T-lymphocyte populations in Parkinson disease. Parkinsonism Relat Disord. 2005;11:493&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pubmed">16154792</ArticleId></ArticleIdList></Reference><Reference><Citation>Bas J, Calopa M, Mestre M, Mollevi DG, Cutillas B, Ambrosio S, Buendia E. Lymphocyte populations in Parkinson's disease and in rat models of parkinsonism. J Neuroimmunol. 2001;113:146&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pubmed">11137586</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Liu Y, Niu Y, Xu Y, Zhou Q, Xu X, Wang J, Yu M. Increased abundance of myeloid-derived suppressor cells and Th17 cells in peripheral blood of newly-diagnosed Parkinson's disease patients. Neurosci Lett. 2017;648:21&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">28359932</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi T, Sakaguchi S. Naturally arising CD25+CD4+ regulatory T cells in maintaining immunologic self-tolerance and preventing autoimmune disease. Curr Mol Med. 2003;3:693&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pubmed">14682491</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung ES, Kim H, Lee G, Park S, Kim H, Bae H. Neuro-protective effects of bee venom by suppression of neuroinflammatory responses in a mouse model of Parkinson's disease: role of regulatory T cells. Brain Behav Immun. 2012;26:1322&#x2013;1330.</Citation><ArticleIdList><ArticleId IdType="pubmed">22974722</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnon R, Aharoni R. Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc Natl Acad Sci U S A. 2004;101(Suppl 2):14593&#x2013;14598.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC521994</ArticleId><ArticleId IdType="pubmed">15371592</ArticleId></ArticleIdList></Reference><Reference><Citation>Putheti P, Soderstrom M, Link H, Huang YM. Effect of glatiramer acetate (Copaxone) on CD4+CD25high T regulatory cells and their IL-10 production in multiple sclerosis. J Neuroimmunol. 2003;144:125&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">14597106</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim NK, Choi BH, Huang X, Snyder BJ, Bukhari S, Kong TH, Park H, Park HC, Park SR, Ha Y. Granulocyte-macrophage colony-stimulating factor promotes survival of dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced murine Parkinson's disease model. Eur J Neurosci. 2009;29:891&#x2013;900.</Citation><ArticleIdList><ArticleId IdType="pubmed">19245369</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou TT, Zu G, Wang X, Zhang XG, Li S, Liang ZH, Zhao J. Immunomodulatory and neuroprotective effects of ginsenoside Rg1 in the MPTP(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) -induced mouse model of Parkinson's disease. Int Immunopharmacol. 2015;29:334&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pubmed">26548343</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Li X, Zhang L, Liu L, Jing G, Cai H. Ginsenoside Rg1 suppressed inflammation and neuron apoptosis by activating PPARgamma/HO-1 in hippocampus in rat model of cerebral ischemia-reperfusion injury. Int J Clin Exp Pathol. 2015;8:2484&#x2013;2494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4440063</ArticleId><ArticleId IdType="pubmed">26045754</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung ES, Lee G, Lee C, Ye M, Chung HS, Kim H, Bae SJ, Hwang DS, Bae H. Bee Venom Phospholipase A2, a Novel Foxp3+ Regulatory T Cell Inducer, Protects Dopaminergic Neurons by Modulating Neuroinflammatory Responses in a Mouse Model of Parkinson's Disease. J Immunol. 2015;195:4853&#x2013;4860.</Citation><ArticleIdList><ArticleId IdType="pubmed">26453752</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen MF, Gill AJ, Kolson DL. Neuropathogenesis of HIV-associated neurocognitive disorders: roles for immune activation, HIV blipping and viral tropism. Curr Opin HIV AIDS. 2014;9:559&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4319532</ArticleId><ArticleId IdType="pubmed">25203638</ArticleId></ArticleIdList></Reference><Reference><Citation>Antinori A, Ammassari A, De Luca A, Cingolani A, Murri R, Scoppettuolo G, Fortini M, Tartaglione T, Larocca LM, Zannoni G, et al. Diagnosis of AIDS-related focal brain lesions: a decision-making analysis based on clinical and neuroradiologic characteristics combined with polymerase chain reaction assays in CSF. Neurology. 1997;48:687&#x2013;694.</Citation><ArticleIdList><ArticleId IdType="pubmed">9065549</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Henkel JS, Zhao W, Wang J, Huang A, Wen S, Liao B, Appel SH. Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. Brain. 2011;134:1293&#x2013;1314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3097891</ArticleId><ArticleId IdType="pubmed">21596768</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassallo M, Durant J, Lebrun-Frenay C, Fabre R, Ticchioni M, Andersen S, DeSalvador F, Harvey-Langton A, Dunais B, Cohen-Codar I, et al. Virologically suppressed patients with asymptomatic and symptomatic HIV-associated neurocognitive disorders do not display the same pattern of immune activation. HIV Med. 2015;16:431&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pubmed">25981452</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Villar S, Moreno S, Fuentes-Ferrer M, Sanchez-Marcos C, Avila M, Sainz T, de Villar NG, Fernandez-Cruz A, Estrada V. The CD4:CD8 ratio is associated with markers of age-associated disease in virally suppressed HIV-infected patients with immunological recovery. HIV Med. 2014;15:40&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">24007533</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P, Mao L, Zhou G, Leak RK, Sun BL, Chen J, Hu X. Adoptive regulatory T-cell therapy preserves systemic immune homeostasis after cerebral ischemia. Stroke. 2013;44:3509&#x2013;3515.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3895539</ArticleId><ArticleId IdType="pubmed">24092548</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P, Gan Y, Sun BL, Zhang F, Lu B, Gao Y, Liang W, Thomson AW, Chen J, Hu X. Adoptive regulatory T-cell therapy protects against cerebral ischemia. Ann Neurol. 2013;74:458&#x2013;471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3748165</ArticleId><ArticleId IdType="pubmed">23674483</ArticleId></ArticleIdList></Reference><Reference><Citation>Grauer OM, Reichelt D, Gruneberg U, Lohmann H, Schneider-Hohendorf T, Schulte-Mecklenbeck A, Gross CC, Meuth SG, Wiendl H, Husstedt IW. Neurocognitive decline in HIV patients is associated with ongoing T-cell activation in the cerebrospinal fluid. Ann Clin Transl Neurol. 2015;2:906&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4574808</ArticleId><ArticleId IdType="pubmed">26401512</ArticleId></ArticleIdList></Reference><Reference><Citation>Marziali M, De Santis W, Carello R, Leti W, Esposito A, Isgro A, Fimiani C, Sirianni MC, Mezzaroma I, Aiuti F. T-cell homeostasis alteration in HIV-1 infected subjects with low CD4 T-cell count despite undetectable virus load during HAART. AIDS. 2006;20:2033&#x2013;2041.</Citation><ArticleIdList><ArticleId IdType="pubmed">17053349</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendez-Lagares G, Pozo-Balado MM, Genebat M, Garcia Perganeda A, Leal M, Pacheco YM. Severe immune dysregulation affects CD4(+)CD25(hi)FoxP3(+) regulatory T cells in HIV-infected patients with low-level CD4 T-cell repopulation despite suppressive highly active antiretroviral therapy. J Infect Dis. 2012;205:1501&#x2013;1509.</Citation><ArticleIdList><ArticleId IdType="pubmed">22457273</ArticleId></ArticleIdList></Reference><Reference><Citation>Valiathan R, Asthana D. Increase in frequencies of circulating Th-17 cells correlates with microbial translocation, immune activation and exhaustion in HIV-1 infected patients with poor CD4 T-cell reconstitution. Immunobiology. 2016;221:670&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pubmed">26817581</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheean RK, McKay FC, Cretney E, Bye CR, Perera ND, Tomas D, Weston RA, Scheller KJ, Djouma E, Menon P, et al. Association of Regulatory T-Cell Expansion With Progression of Amyotrophic Lateral Sclerosis: A Study of Humans and a Transgenic Mouse Model. JAMA Neurol. 2018;75:681&#x2013;689.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5885208</ArticleId><ArticleId IdType="pubmed">29507931</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Xia Y, Ye Q, Yu F, Zhu W, Li P, Wei Z, Yang Y, Shi Y, Thomson AW, et al. In Vivo Expansion of Regulatory T Cells with IL-2/IL-2 Antibody Complex Protects against Transient Ischemic Stroke. J Neurosci. 2018;38:10168&#x2013;10179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6246882</ArticleId><ArticleId IdType="pubmed">30291203</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaardbo JC, Nielsen SD, Vedel SJ, Ersboll AK, Harritshoj L, Ryder LP, Nielsen JO, Kolte L. Regulatory T cells in human immunodeficiency virus-infected patients are elevated and independent of immunological and virological status, as well as initiation of highly active anti-retroviral therapy. Clin Exp Immunol. 2008;154:80&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2561082</ArticleId><ArticleId IdType="pubmed">18821942</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinman AJ, Sivanandham R, Pandrea I, Chougnet CA, Apetrei C. Regulatory T Cells As Potential Targets for HIV Cure Research. Front Immunol. 2018;9:734.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5908895</ArticleId><ArticleId IdType="pubmed">29706961</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambada GN, Ntsama CE, Nji NN, Ngu LN, Sake CN, Lissom A, Tchouangeu FT, Tchadji J, Sosso M, Etoa FX, Nchinda GW. Phenotypic characterization of regulatory T cells from antiretroviral-naive HIV-1-infected people. Immunology. 2017;151:405&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5506422</ArticleId><ArticleId IdType="pubmed">28375551</ArticleId></ArticleIdList></Reference><Reference><Citation>Chevalier MF, Weiss L. The split personality of regulatory T cells in HIV infection. Blood. 2013;121:29&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">23043072</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, Burrell JR, Zoing MC. Amyotrophic lateral sclerosis. Lancet. 2011;377:942&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Appel SH. Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies. Lancet Neurol. 2019;18:211&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">30663610</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Zhao W, Appel SH. The Role of Regulatory T Lymphocytes in Amyotrophic Lateral Sclerosis. JAMA Neurol. 2018;75:656&#x2013;658.</Citation><ArticleIdList><ArticleId IdType="pubmed">29507936</ArticleId></ArticleIdList></Reference><Reference><Citation>Troost D, van den Oord JJ, de Jong JM, Swaab DF. Lymphocytic infiltration in the spinal cord of patients with amyotrophic lateral sclerosis. Clin Neuropathol. 1989;8:289&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pubmed">2533530</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawamata T, Akiyama H, Yamada T, McGeer PL. Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am J Pathol. 1992;140:691&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1886170</ArticleId><ArticleId IdType="pubmed">1347673</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelhardt JI, Tajti J, Appel SH. Lymphocytic infiltrates in the spinal cord in amyotrophic lateral sclerosis. Arch Neurol. 1993;50:30&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">8093428</ArticleId></ArticleIdList></Reference><Reference><Citation>Graves MC, Fiala M, Dinglasan LA, Liu NQ, Sayre J, Chiappelli F, van Kooten C, Vinters HV. Inflammation in amyotrophic lateral sclerosis spinal cord and brain is mediated by activated macrophages, mast cells and T cells. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5:213&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">15799549</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Henkel JS, Zhao W, Wang J, Appel SH. CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. Proc Natl Acad Sci U S A. 2008;105:15558&#x2013;15563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2547419</ArticleId><ArticleId IdType="pubmed">18809917</ArticleId></ArticleIdList></Reference><Reference><Citation>Saresella M, Piancone F, Tortorella P, Marventano I, Gatti A, Caputo D, Lunetta C, Corbo M, Rovaris M, Clerici M. T helper-17 activation dominates the immunologic milieu of both amyotrophic lateral sclerosis and progressive multiple sclerosis. Clin Immunol. 2013;148:79&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">23665549</ArticleId></ArticleIdList></Reference><Reference><Citation>Rentzos M, Evangelopoulos E, Sereti E, Zouvelou V, Marmara S, Alexakis T, Evdokimidis I. Alterations of T cell subsets in ALS: a systemic immune activation? Acta Neurol Scand. 2012;125:260&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">21651502</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, Beers DR, Wen S, Rivera AL, Toennis KM, Appel JE, Zhao W, Moore DH, Powell SZ, Appel SH. Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol Med. 2013;5:64&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3569654</ArticleId><ArticleId IdType="pubmed">23143995</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Zhao W, Wang J, Zhang X, Wen S, Neal D, Thonhoff JR, Alsuliman AS, Shpall EJ, Rezvani K, Appel SH. ALS patients' regulatory T lymphocytes are dysfunctional, and correlate with disease progression rate and severity. JCI Insight. 2017;2:e89530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5333967</ArticleId><ArticleId IdType="pubmed">28289705</ArticleId></ArticleIdList></Reference><Reference><Citation>Thonhoff JR, Beers DR, Zhao W, Pleitez M, Simpson EP, Berry JD, Cudkowicz ME, Appel SH. Expanded autologous regulatory T-lymphocyte infusions in ALS: A phase I, first-in-human study. Neurol Neuroimmunol Neuroinflamm. 2018;5:e465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5961523</ArticleId><ArticleId IdType="pubmed">29845093</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry JD, Paganoni S, Atassi N, Macklin EA, Goyal N, Rivner M, Simpson E, Appel S, Grasso DL, Mejia NI, et al. Phase IIa trial of fingolimod for amyotrophic lateral sclerosis demonstrates acceptable acute safety and tolerability. Muscle Nerve. 2017;56:1077&#x2013;1084.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5724488</ArticleId><ArticleId IdType="pubmed">28662296</ArticleId></ArticleIdList></Reference><Reference><Citation>Potenza RL, De Simone R, Armida M, Mazziotti V, Pezzola A, Popoli P, Minghetti L. Fingolimod: A Disease-Modifier Drug in a Mouse Model of Amyotrophic Lateral Sclerosis. Neurotherapeutics. 2016;13:918&#x2013;927.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5081121</ArticleId><ArticleId IdType="pubmed">27456702</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Gong N, Huang X, Reynolds AD, Mosley RL, Gendelman HE. Neuromodulatory activities of CD4+CD25+ regulatory T cells in a murine model of HIV-1-associated neurodegeneration. J Immunol. 2009;182:3855&#x2013;3865.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2661207</ArticleId><ArticleId IdType="pubmed">19265165</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia Y, Cai W, Thomson AW, Hu X. Regulatory T Cell Therapy for Ischemic Stroke: how far from Clinical Translation? Transl Stroke Res. 2016;7:415&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5179138</ArticleId><ArticleId IdType="pubmed">27307291</ArticleId></ArticleIdList></Reference><Reference><Citation>Sairanen T, Karjalainen-Lindsberg ML, Paetau A, Ijas P, Lindsberg PJ. Apoptosis dominant in the periinfarct area of human ischaemic stroke--a possible target of antiapoptotic treatments. Brain. 2006;129:189&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pubmed">16272167</ArticleId></ArticleIdList></Reference><Reference><Citation>Brait VH, Arumugam TV, Drummond GR, Sobey CG. Importance of T lymphocytes in brain injury, immunodeficiency, and recovery after cerebral ischemia. J Cereb Blood Flow Metab. 2012;32:598&#x2013;611.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3318155</ArticleId><ArticleId IdType="pubmed">22293986</ArticleId></ArticleIdList></Reference><Reference><Citation>McColl BW, Rothwell NJ, Allan SM. Systemic inflammatory stimulus potentiates the acute phase and CXC chemokine responses to experimental stroke and exacerbates brain damage via interleukin-1- and neutrophil-dependent mechanisms. J Neurosci. 2007;27:4403&#x2013;4412.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672305</ArticleId><ArticleId IdType="pubmed">17442825</ArticleId></ArticleIdList></Reference><Reference><Citation>Konoeda F, Shichita T, Yoshida H, Sugiyama Y, Muto G, Hasegawa E, Morita R, Suzuki N, Yoshimura A. Therapeutic effect of IL-12/23 and their signaling pathway blockade on brain ischemia model. Biochem Biophys Res Commun. 2010;402:500&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pubmed">20965150</ArticleId></ArticleIdList></Reference><Reference><Citation>Yilmaz G, Arumugam TV, Stokes KY, Granger DN. Role of T lymphocytes and interferon-gamma in ischemic stroke. Circulation. 2006;113:2105&#x2013;2112.</Citation><ArticleIdList><ArticleId IdType="pubmed">16636173</ArticleId></ArticleIdList></Reference><Reference><Citation>Llovera G, Hofmann K, Roth S, Salas-Perdomo A, Ferrer-Ferrer M, Perego C, Zanier ER, Mamrak U, Rex A, Party H, et al. Results of a preclinical randomized controlled multicenter trial (pRCT): Anti-CD49d treatment for acute brain ischemia. Sci Transl Med. 2015;7:&#x2013;299ra121.</Citation><ArticleIdList><ArticleId IdType="pubmed">26246166</ArticleId></ArticleIdList></Reference><Reference><Citation>Liesz A, Dalpke A, Mracsko E, Antoine DJ, Roth S, Zhou W, Yang H, Na SY, Akhisaroglu M, Fleming T, et al. DAMP signaling is a key pathway inducing immune modulation after brain injury. J Neurosci. 2015;35:583&#x2013;598.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4293412</ArticleId><ArticleId IdType="pubmed">25589753</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C, Anrather J. The immunology of stroke: from mechanisms to translation. Nat Med. 2011;17:796&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3137275</ArticleId><ArticleId IdType="pubmed">21738161</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamel H, Iadecola C. Brain-immune interactions and ischemic stroke: clinical implications. Arch Neurol. 2012;69:576&#x2013;581.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3586409</ArticleId><ArticleId IdType="pubmed">22782509</ArticleId></ArticleIdList></Reference><Reference><Citation>Li GZ, Zhong D, Yang LM, Sun B, Zhong ZH, Yin YH, Cheng J, Yan BB, Li HL. Expression of interleukin-17 in ischemic brain tissue. Scand J Immunol. 2005;62:481&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">16305645</ArticleId></ArticleIdList></Reference><Reference><Citation>Shichita T, Sugiyama Y, Ooboshi H, Sugimori H, Nakagawa R, Takada I, Iwaki T, Okada Y, Iida M, Cua DJ, et al. Pivotal role of cerebral interleukin-17-producing gammadeltaT cells in the delayed phase of ischemic brain injury. Nat Med. 2009;15:946&#x2013;950.</Citation><ArticleIdList><ArticleId IdType="pubmed">19648929</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y, Zhou Y, Xiao W, Liang Z, Dai J, Weng X, Wu X. Interleukin-33 ameliorates ischemic brain injury in experimental stroke through promoting Th2 response and suppressing Th17 response. Brain Res. 2015;1597:86&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">25500143</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Y, Chen X, Li D, Liu H, Ding Y, Han R, Shi Y, Ma X. PR-957 mediates neuroprotection by inhibiting Th17 differentiation and modulating cytokine production in a mouse model of ischaemic stroke. Clin Exp Immunol. 2018;193:194&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6046491</ArticleId><ArticleId IdType="pubmed">29603201</ArticleId></ArticleIdList></Reference><Reference><Citation>Stubbe T, Ebner F, Richter D, Engel O, Klehmet J, Royl G, Meisel A, Nitsch R, Meisel C, Brandt C. Regulatory T cells accumulate and proliferate in the ischemic hemisphere for up to 30 days after MCAO. J Cereb Blood Flow Metab. 2013;33:37&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3597367</ArticleId><ArticleId IdType="pubmed">22968321</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinschnitz C, Kraft P, Dreykluft A, Hagedorn I, Gobel K, Schuhmann MK, Langhauser F, Helluy X, Schwarz T, Bittner S, et al. Regulatory T cells are strong promoters of acute ischemic stroke in mice by inducing dysfunction of the cerebral microvasculature. Blood. 2013;121:679&#x2013;691.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3790947</ArticleId><ArticleId IdType="pubmed">23160472</ArticleId></ArticleIdList></Reference><Reference><Citation>Liesz A, Suri-Payer E, Veltkamp C, Doerr H, Sommer C, Rivest S, Giese T, Veltkamp R. Regulatory T cells are key cerebroprotective immunomodulators in acute experimental stroke. Nat Med. 2009;15:192&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pubmed">19169263</ArticleId></ArticleIdList></Reference><Reference><Citation>Urra X, Cervera A, Villamor N, Planas AM, Chamorro A. Harms and benefits of lymphocyte subpopulations in patients with acute stroke. Neuroscience. 2009;158:1174&#x2013;1183.</Citation><ArticleIdList><ArticleId IdType="pubmed">18619524</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong N, Liu J, Reynolds AD, Gorantla S, Mosley RL, Gendelman HE. Brain ingress of regulatory T cells in a murine model of HIV-1 encephalitis. J Neuroimmunol. 2011;230:33&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3003943</ArticleId><ArticleId IdType="pubmed">20846730</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X, Stone DK, Yu F, Zeng Y, Gendelman HE. Functional proteomic analysis for regulatory T cell surveillance of the HIV-1-infected macrophage. J Proteome Res. 2010;9:6759&#x2013;6773.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3108468</ArticleId><ArticleId IdType="pubmed">20954747</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Fernandez ME, Rueda CM, Rusie LK, Chougnet CA. Regulatory T cells control HIV replication in activated T cells through a cAMP-dependent mechanism. Blood. 2011;117:5372&#x2013;5380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3109711</ArticleId><ArticleId IdType="pubmed">21436067</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinter A, McNally J, Riggin L, Jackson R, Roby G, Fauci AS. Suppression of HIV-specific T cell activity by lymph node CD25+ regulatory T cells from HIV-infected individuals. Proc Natl Acad Sci U S A. 2007;104:3390&#x2013;3395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1805624</ArticleId><ArticleId IdType="pubmed">17360656</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessler PA. Potential Role of Regulatory T Cells in Mother-to-Child Transmission of HIV. Curr HIV Res. 2018;16:396&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6446459</ArticleId><ArticleId IdType="pubmed">30760190</ArticleId></ArticleIdList></Reference><Reference><Citation>Group I-ES. Committee SS, Abrams D, Levy Y, Losso MH, Babiker A, Collins G, Cooper DA, Darbyshire J, Emery S, et al. Interleukin-2 therapy in patients with HIV infection. N Engl J Med. 2009;361:1548&#x2013;1559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2869083</ArticleId><ArticleId IdType="pubmed">19828532</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss L, Letimier FA, Carriere M, Maiella S, Donkova-Petrini V, Targat B, Benecke A, Rogge L, Levy Y. In vivo expansion of naive and activated CD4+CD25+FOXP3+ regulatory T cell populations in interleukin-2-treated HIV patients. Proc Natl Acad Sci U S A. 2010;107:10632&#x2013;10637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2890853</ArticleId><ArticleId IdType="pubmed">20498045</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Fernandez ME, Zapata W, Blackard JT, Franchini G, Chougnet CA. Human regulatory T cells are targets for human immunodeficiency Virus (HIV) infection, and their susceptibility differs depending on the HIV type 1 strain. J Virol. 2009;83:12925&#x2013;12933.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2786841</ArticleId><ArticleId IdType="pubmed">19828616</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss L, Piketty C, Assoumou L, Didier C, Caccavelli L, Donkova-Petrini V, Levy Y, Girard PM, Burgard M, Viard JP, et al. Relationship between regulatory T cells and immune activation in human immunodeficiency virus-infected patients interrupting antiretroviral therapy. PLoS One. 2010;5:e11659.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2908121</ArticleId><ArticleId IdType="pubmed">20657770</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, Nunoya JI, Cheng L, Reszka-Blanco N, Tsao LC, Jeffrey J, Su L. Regulatory T Cells Contribute to HIV-1 Reservoir Persistence in CD4+ T Cells Through Cyclic Adenosine Monophosphate-Dependent Mechanisms in Humanized Mice In Vivo. J Infect Dis. 2017;216:1579&#x2013;1591.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5853220</ArticleId><ArticleId IdType="pubmed">29045701</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiao YM, Liu CE, Luo LJ, Zhu WJ, Zhang T, Zhang LG, Su LS, Li HJ, Wu H. CD4+CD25+CD127 regulatory cells play multiple roles in maintaining HIV-1 p24 production in patients on long-term treatment: HIV-1 p24-producing cells and suppression of anti-HIV immunity. Int J Infect Dis. 2015;37:42&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">26095899</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran TA, de Goer de Herve MG, Hendel-Chavez H, Dembele B, Le Nevot E, Abbed K, Pallier C, Goujard C, Gasnault J, Delfraissy JF, et al. Resting regulatory CD4 T cells: a site of HIV persistence in patients on long-term effective antiretroviral therapy. PLoS One. 2008;3:e3305.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2551739</ArticleId><ArticleId IdType="pubmed">18827929</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathews S, Branch Woods A, Katano I, Makarov E, Thomas MB, Gendelman HE, Poluektova LY, Ito M, Gorantla S. Human Interleukin-34 facilitates microglia-like cell differentiation and persistent HIV-1 infection in humanized mice. Mol Neurodegener. 2019;14:12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6399898</ArticleId><ArticleId IdType="pubmed">30832693</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>